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AbsTrACT
Aims To describe a large tertiary care academic 
centre’s experience with patients who achieve a 
complete pathological response (ie, ypT0N0) following 
neoadjuvant chemotherapy (NAC) and radical cystectomy 
(RC) with emphasis on morphological features present in 
the RC and clinical outcome.
Methods 41 patients with ypT0N0 disease following 
transurethral resection of bladder tumour (TURBT), NAC 
and RC with available clinical follow-up information 
were analysed. Slides from all RCs were reviewed to 
confirm pathological stage and assess for morphological 
parameters (eg, foreign body giant cell reaction, 
dystrophic calcification, scar and fat necrosis).
results With median follow-up of 32.8 months, the 
recurrence-free survival at 1 and 5 years was 97.4% 
and 93.5%, while the overall survival at 3 and 5 years 
was 94.2% and 88.6%, respectively. No patients died 
of urothelial carcinoma. Stage assigned at TURBT was 
1 pTa (2%), 1 pT1 (2%), 38 pT2 (93%) and 1 pT3a 
(2%). 17 TURBTs demonstrated variant histology, with 
the majority of these being squamous (65%). The most 
common morphological features present at RC were 
scar (100%), foreign body giant cell reaction (80%), 
chronic inflammation within lamina propria (68%) and 
dystrophic calcifications (39%). Other morphological 
features were less common or absent.
Conclusion ypT0N0 disease at RC portends an 
excellent prognosis, regardless of stage or variant 
histology in the TURBT; scar, foreign body giant 
cell reaction, chronic inflammation and dystrophic 
calcifications are often present.
InTrOduCTIOn
Urothelial carcinoma (UC) of the urinary bladder is 
one of the most common types of cancer, with more 
than 80 470 expected new diagnoses and 17 670 
expected deaths in the USA in 2019.1 Clearly, UC 
of the urinary bladder confers significant mortality, 
and patients often require an aggressive therapeutic 
strategy. UC of the urinary bladder is now often 
treated with radical cystectomy (RC) and lymph 
node dissection following transurethral resection of 
bladder tumour (TURBT) and neoadjuvant chemo-
therapy (NAC).2–5 Thus, no residual tumour may be 
present in the RC specimen (ypT0) or lymph nodes 
(pN0).6
Historically, the incidence of stage ypT0 bladder 
carcinoma was approximately 10%.7–12 With 
increased utilisation of NAC, however, the incidence 
of stage ypT0 bladder carcinoma may be increasing, 
and recent studies show a stage ypT0 incidence of 
nearly 30% following NAC.13–16 Indeed, a primary 
benefit of NAC may be that it increases a patient’s 
chance of achieving stage ypT0, and these patients 
experience better overall survival (OS) and recur-
rence-free survival (RFS) than patients without a 
complete pathological response.13 16–20 Neverthe-
less, unfavourable outcomes can occur in patients 
with ypT0, and this is likely due to extraves-
ical spread prior to RC. Lymph node metastases 
in patients with ypT0 are rare, with 3%–7% of 
patients developing nodal metastasis.8 11
As stage ypT0 bladder carcinoma is more 
frequently encountered at RC, surgical pathologists 
and urologists must become comfortable with the 
absence of residual tumour in the RC and lymph 
node dissection.21 However, detailed descrip-
tion of clinicopathological characteristics of stage 
ypT0N0 RC specimens following TURBT and 
NAC is lacking in the literature. Here, we describe 
a large tertiary care academic centre’s experience 
with patients who achieve a complete pathological 
response (ie, ypT0N0) following NAC and RC with 
emphasis on morphological features present in the 
RC and clinical outcome.
MeThOds
Patients with stage ypT0N0 disease following 
TURBT, NAC and RC with available clinical 
follow-up were identified from the pathology 
and urology records at Indiana University over a 
10-year period (January 2007 to December 2017).
All patients underwent cystectomy with curative
intent. Urinary diversion technique was decided
based on tumour characteristics, surgeon and/or
patient preference. An extended template pelvic
lymph node dissection (with the bifurcation of the
great vessels representing the proximal limit of
lymphadenectomy) is the standard dissection at the
Indiana University. Patient demographic data (age,
gender, and so on) were listed in table 1.
RCs included in the study were grossed by expe-
rienced pathologists’ assistants (PA) or pathology 
trainees under the guidance of experienced PAs. 
In all cases, any grossly suspicious areas of the 
urinary bladder were sampled. Submission of the 
entire urinary bladder mucosa was not performed, 
but in some cases additional sections of the urinary 
bladder were submitted. Slides from all RCs and 
lymph node dissections were reviewed to confirm 
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Table 1 Clinicopathological parameters
Characteristics % (Patients, n)
Gender
 Male 83 (34)
 Female 17 (7)
Age (years)
 Range 45–78
 Mean 61
 Median 60
Stage of TURB
 pTa 2 (1)
 pT1 2 (1)
 ≥pT2 95 (39)
CIS present
 Yes 29 (10)
 No 71 (25)
Variant histology in TURB
 Squamous 65 (11)*
 Sarcomatoid* 6 (1)*
 Micropapillary 12 (2)
 Plasmacytoid 6 (1)
 Glandular 6 (1)
 Other 12 (2)
*One patient had both squamous and sarcomatoid differentiation.
CIS, carcinoma in situ; TURBT, transurethral resection of bladder tumour.
Table 2 Histological parameters observed in radical cystectomy 
specimens
Characteristics % (Patients, n)
Urothelial dysplasia 10 (4)
Mucosal ulceration 17 (7)
Extensively denuding mucosa 17 (7)
Keratinising squamous metaplasia 5 (2)
Viral inclusions 0 (0)
Foreign body giant cell reaction 80 (33)
Dystrophic calcifications 39 (16)
Scar 100 (41)
Fat necrosis 10 (4)
Mucosa
 Acute inflammation 17 (7)
 Chronic inflammation 15 (6)
 Histiocytic inflammation 10 (4)
Lamina propria
 Acute inflammation 17 (7)
 Chronic inflammation 15 (6)
 Histiocytic inflammation 10 (4)
pathological stage of ypT0 and nodal stage of pN0. Additionally, 
the presence or absence of various histological parameters (eg, 
foreign body giant cell reaction, dystrophic calcification, scar 
and fat necrosis) was recorded. Surgical pathology reports from 
prior TURBTs were reviewed.
Patients were subjected to NAC followed by RC at the discre-
tion of a multidisciplinary team of physicians in consultation 
with each patient based on clinical and pathological informa-
tion available. Indeed, at Indiana University almost all patients 
with muscle invasive UC of the urinary bladder are evaluated by 
medical oncology for consideration of cisplatin-based NAC or 
enrolment on neoadjuvant therapy clinical trials. Patients who 
are cisplatin eligible (glomerular filtration rate >60, no grade 
≥2 neuropathy, no hearing loss, Eastern Cooperative Oncology 
Group performance status <2, no New York Heart Association 
class 3 congestive heart failure) are offered neoadjuvant cispla-
tin-based chemotherapy with dose-dense methotrexate, vinblas-
tine, doxorubicin and cisplatin (MVAC). In all, approximately 
two-thirds of patients receive NAC at Indiana University.
During follow-up periods, patients were periodically evalu-
ated for evidence of recurrence. Patients were closely followed 
by a multidisciplinary team with imaging of the upper urinary 
tract together with abdomen and pelvis (CT or MRI urography), 
plus chest CT or chest X-ray every 4–6 months in the first 2 
years, and then every 6–12 months afterwards. Urine cytology 
and urethral wash were done every 6–12 months in the first 
2 years then as clinically indicated. Recurrence was defined as 
biopsy proven or having radiographical evidence of local or 
distant failure. Survival outcomes were calculated from the time 
of RC to date of death or last follow-up. Time to recurrence 
was estimated from the time of the cystectomy until the date 
of recurrence diagnosis by imaging or last follow-up. Addition-
ally, OS and RFS after the cystectomy were appraised using the 
Kaplan-Meier method. Cancer-specific survival was not assessed 
since there were no cancer-related deaths in this patient cohort. 
Statistical analyses were performed using Stata statistical soft-
ware release V.15 (StataCorp, College Station, TX, USA).
resulTs
Forty-one patients with ypT0N0 who underwent NAC followed 
by RC were identified from the prospectively maintained 
pathology and urology databases at Indiana University (table 1). 
Of these, 34 were male, and seven were female. The mean age 
at RC was 61 years old (median 60 years, range 45–78 years). 
Thirty-one patients received gemcitabine and cisplatin chemo-
therapy while 10 patients received MVAC. The pathological 
stage assigned at TURBT was known in all patients, and most 
(n=38, 93%) were pT2 (ie, invasive into muscularis propria). 
The remaining patients were pTa (n=1, 2%; ie, non-invasive 
papillary UC), pT1 (n=1, 2%; ie, invasive into lamina propria) or 
pT3a (n=1, 2%; ie, invasive into perivesical adipose). Although 
the true pathological stage is assigned to the RC specimen in 
accordance with the American Joint Committee on Cancer 
Staging Manual, Eighth Edition, at our institution a preliminary 
‘pT’ stage is assigned to the TURBT specimen to guide patient 
management.6 22 The presence or absence of urothelial carci-
noma in situ (CIS) in the TURBT was known in 35 patients; of 
these, CIS was present in 10 (29%) TURBTs. Fifteen patients 
had a variant histology of UC present in the TURBT. Squamous 
differentiation was the most common variant histology (n=11, 
65%), and one patient had both squamous and sarcomatoid 
differentiation (n=1, 6%). Micropapillary (n=2, 12%), plas-
macytoid (n=1, 6%) and glandular (n=1, 6%) differentiation 
were also reported in the TURBTs; 2 (12%) cases were reported 
only as ‘other’. Muscularis propria was present in all TURBTs. 
Lymphovascular invasion was present in two TURBT specimens; 
these patients did not have lymph node metastases identified at 
the time of RC and lymph node dissection.
The most common histological findings present at cystectomy 
were scar (n=41, 100%, table 2, figure 1), foreign body giant 
cell reaction (n=33, 80%), chronic inflammation within lamina 
propria (n=28, 68%) and dystrophic calcifications (n=16, 
39%). Fat necrosis was present in 4 (10%) RCs, including the 
single patient with invasion into perivesical adipose (stage pT3a) 
in the previous TURBT. Urothelial dysplasia, defined as atypia 
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Figure 1 Histopathological appearance of ypT0N0 bladder cancer. 
Scar was present in the lamina propria of all radical cystectomy (RC) 
specimens (A, H&E, 100×). Other histological features which were 
frequently identified were foreign body giant cell reaction (B, H&E, 
200×), chronic inflammation within the lamina propria and dystrophic 
calcifications (C, H&E, 200×). Mucosal ulceration was also sometimes 
present (17%, D, H&E, 100×). Fat necrosis was identified in 4 (10%) 
RCs, including the single patient with invasion into perivesical adipose 
diagnosed in the previous transurethral resection of bladder tumour 
(TURBT) (E, H&E, 200×). Keratinising squamous metaplasia was rarely 
present (5%, F, H&E, 200×).
Figure 2 (A) Recurrence-free survival and (B) overall survival for 
ypT0N0 bladder cancer.
more consistent with neoplasia than reactive changes but without 
reaching the threshold of CIS, was present in 4 (10%) RCs; 
two of these patients had CIS present in the previous TURBT 
while two did not. In addition to chronic inflammation within 
the lamina propria, acute inflammation (n=1, 2%) and histio-
cytic inflammation (n=4, 10%) were also present in the lamina 
propria. The surface urothelium was involved by acute inflam-
mation in 7 (17%) RCs, chronic inflammation in 6 (15%) RCs 
and histiocytic inflammation in 4 (10%) RCs. Other histological 
findings identified in the RCs were mucosal ulceration (n=7, 
17%), extensively denuding mucosa (n=7, 17%) and kerati-
nising squamous metaplasia (n=2, 5%). Features which were 
specifically assessed but not identified in any of the RC speci-
mens were cystitis glandularis with intestinal metaplasia (n=0, 
0%), viral inclusions (n=0, 0%), foreign body giant cell reaction 
associated with cholesterol clefts (n=0, 0%) and vascular fibro-
elastotic stroma with macrophages (n=0, 0%).
In all, three patients died in this cohort. Two died as a result 
of postoperative complications; one death was due to a compli-
cated intra-abdominal abscess, and the other was due to a 
pulmonary embolism. The cause of death of the third patient 
is unknown. Furthermore, during the follow-up period only 2 
(4.9%) patients developed cancer recurrence. One of the recur-
rences was found on the right adrenal by a positron emission 
tomography/CT 19.9 months after the RC and was treated only 
with adrenalectomy; this patient had no evidence of disease 42.7 
months after RC. The second patient was put on atezolizumab 
for 6 months after a CT showed upper urinary tract recurrence 
2.1 months after surgery. She showed no evidence of disease at 
her last follow-up 14.9 months after RC. The median follow-up 
after RC was 32.80 (IQR: 13.33, 60.90) months. Furthermore, 
at 1 and 5 years, the RFS was 97.37% and 93.47%, while the 
OS at 3 and 5 years was 94.16% and 88.62%, respectively. The 
Kaplan-Meier curves for OS and RFS are shown in figure 2.
dIsCussIOn
In the present study, we reviewed the RC specimen and lymph 
node dissections of 41 patients with ypT0N0 following NAC 
and RC. By definition, none of the patients had any residual 
UC, either in the urinary bladder or in the lymph nodes, and 
these patients had exceptionally good outcomes, with none of 
the patients dying from UC. Most of these patients had aggres-
sive, muscle-invasive UC prior to NAC, and a notable subset 
of them had aggressive morphological variants present in their 
TURBT (ie, micropapillary, plasmacytoid or sarcomatoid differ-
entiation). Thus, NAC followed by RC appears to be appropriate 
management for at least a subset of patients with UC.13 16–20
As NAC followed by RC increases the proportion of patients 
who achieve ypT0N0, surgical pathologists will more frequently 
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encounter RC and lymph node dissections, which lack any 
residual UC in patients with a history of aggressive, muscle-in-
vasive UC. Clearly, meticulous gross examination of the surgical 
resection specimen(s) coupled with histological analysis of any 
grossly suspicious areas is necessary prior to assigning ypT0N0, 
given the important prognostic implications. However, it would 
also be unreasonable to expect histological examination of 
the entire RC specimen prior to assigning ypT0N0.23 24 With 
histological undersampling and oversampling of the urinary 
bladder at two ends of a spectrum, there is clearly an appro-
priate midpoint, which involves meticulous gross examination 
coupled with submission of a reasonable number of blocks for 
histological analysis. For the surgical pathologist who has yet 
to routinely encounter ypT0N0 RC specimens, however, this 
midpoint may be difficult to find.
For this reason, we sought to provide histological param-
eters, which may be associated with UC effectively treated by 
NAC. To that end, the most common histological findings of 
ypT0N0 RC specimens in our study were scar (100%), foreign 
body giant cell reaction (80%) and chronic inflammation in the 
lamina propria (68%). These findings are not surprising, but, 
nonetheless, they support the fact that a RC specimen has been 
adequately sampled. Importantly, the presence of scar was the 
only truly ubiquitous histological parameter, and chronic inflam-
mation and a foreign body giant cell reaction were not present 
in all cases.
In summary, stage ypT0N0 portends an excellent prognosis 
in patients with UC following NAC and RC. Assignment of 
ypT0N0 should only occur following a meticulous gross exam-
ination of the urinary bladder with histological sampling of any 
suspicious areas. If a scar is present in the examined sections, 
the surgical pathologist can be confident that the appropriate 
area of the urinary bladder was examined. The presence of a 
foreign body giant cell reaction and/or chronic inflammation 
in the lamina propria can also further support the notion that 
a urinary bladder was adequately sampled, but they may not 
always be present.
Take home messages
 ► Urinary bladder cancer is often treated with neoadjuvant
chemotherapy and radical cystectomy.
 ► The incidence of complete pathological response (ypT0) in
this setting is increasing.
 ► Scar and foreign body giant cell reaction are present in
cystectomies lacking residual tumour.
 ► Patients who achieve ypT0N0 have an excellent prognosis.
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